Union Health Ministry has lifted the ban on retail sale of Oxytocin with some regulations.
It is an essential drug used to prevent and treat bleeding after childbirth.
In another amendment to the original notification, the ministry has banned the private manufacture and retailing of Oxytocin while retaining the monopoly of the public sector on manufacturing the drug for the domestic market.
The ban came in the light of complaints of rampant misuse of the drug in the dairy industry in particular.
The new rules also stated that with effect from September 1, 2018, Oxytocin will be moved from schedule H to schedule H1.
It is to be noted that drugs under schedule H can only be sold against a prescription by a registered medical practitioner.
In the case of those under H1, a schedule introduced in 2013 to prevent misuse of third and fourth generation antibiotics, the retailer has to maintain a separate register giving the name and address of the prescriber, the patient, the drug and the quantity supplied.